Literature DB >> 8666803

Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.

E Prina1, T Lang, N Glaichenhaus, J C Antoine.   

Abstract

Macrophages are apparently the only cells that in vivo allow the growth of the intracellular pathogen Leishmania. They are thus generally considered as likely candidates for the presentation of parasite Ag to CD4+ T lymphocytes known to be involved in protective and counterprotective immune responses. In the present study, we examined whether mouse macrophages infected with Leishmania were capable of stimulating T cell hybrids and a T cell clone reacting with the previously identified protective Ag LACK (Leishmania homologue of receptors for Activated C Kinase). This parasite protein is expressed in both promastigote and amastigote stages of Leishmania. We found that IFN-gamma-treated macrophages recently infected with live Leishmania promastigotes were fully competent to activate LACK-reactive T cells. However, at later times of infection, permissive macrophages infected with promastigotes were no longer able to present LACK, in spite of the presence of numerous intracellular parasites. This punctual presentation of LACK was apparently linked with the destruction, at least partial, of the intracellular parasites. In contrast, macrophages infected with live Leishmania amastigotes were always unable to stimulate the LACK-specific T cells. Amastigote-infected macrophages could, however, reactivate the T cells if LACK-delta(1), a recombinant form of LACK, was added as an exogenous protein in the culture medium. Similar results were obtained with all combinations tested involving macrophages from various origins, different activating cytokines (IFN-gamma, granulocyte-macrophage CSF, IL-4), several Leishmania species (L. amazonensis, L. major, L. donovani), and 15 different LACK-reactive T cell hybrids and clones. From these data, it is tempting to propose that the differentiation of promastigotes into amastigotes, which leads to a better survival of the parasites within macrophages, also allows them to go unnoticed by the immune system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666803

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Down-regulation of MHC class II molecules and inability to up-regulate class I molecules in murine macrophages after infection with Toxoplasma gondii.

Authors:  C G Lüder; T Lang; B Beuerle; U Gross
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

3.  Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.

Authors:  I B Kremer; M P Gould; K D Cooper; F P Heinzel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

5.  The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum.

Authors:  Thierry Lang; Nathalie Courret; Jean-Hervé Colle; Geneviève Milon; Jean-Claude Antoine
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Capacity of mouse mast cells to prime T cells and to induce specific antibody responses in vivo.

Authors:  I Villa; D Skokos; C Tkaczyk; R Peronet; B David; M Huerre; S Mécheri
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

7.  Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.

Authors:  N Soussi; G Milon; J H Colle; E Mougneau; N Glaichenhaus; P L Goossens
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.

Authors:  F A Torrentera; N Glaichenhaus; J D Laman; Y Carlier
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

9.  Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions.

Authors:  Dong Liu; Chahnaz Kebaier; Nazzy Pakpour; Althea A Capul; Stephen M Beverley; Phillip Scott; Jude E Uzonna
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

10.  Interferon gamma in leishmaniasis.

Authors:  Peter E Kima; Lynn Soong
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.